Evidence map›Paper›PMID 38323410›Full record

Observational studyAnnals of surgery2025

A Novel Serum Exosomal MicroRNA Signature in the Early Prediction of Persistent Organ Failure in Patients With Acute Pancreatitis.

Lei Li, Qichen Zhang, Yongpu Feng, Fanyang Kong, Fengyuan Sun, Pei Xie, Jiangman Zhao, Hang Yu, Jiahuan Zhou, Shouxin Wu and 5 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02602808 (Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02602808 completednot on this map

Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis

TypeobservationalSponsorChanghai HospitalRan2015 to 2019Enrolled1,097ConditionsAcute Pancreatitis
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Lei LiChanghai Clinical Research Unit, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.
Qichen ZhangPancreatic Intensive Care Unit, Changhai Hospital, Naval Medical University, Shanghai, China.
Yongpu FengDigestive Endoscopy Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Fanyang KongChanghai Clinical Research Unit, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.
Fengyuan SunPancreatic Intensive Care Unit, Changhai Hospital, Naval Medical University, Shanghai, China.
Pei XieDigestive Endoscopy Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Jiangman ZhaoShanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai Zhangjiang Institute of Medical Innovation, Shanghai, China.
Hang YuTrauma Emergency Rescue Center, Naval Medical University, Shanghai, China.
Jiahuan ZhouShanghai Biotecan Pharmaceuticals Co., Ltd, Shanghai Zhangjiang Institute of Medical Innovation, Shanghai, China.
Shouxin WuShanghai Jiuji Co., Ltd, Shanghai, China.
Shengbing ZhaoChanghai Clinical Research Unit, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.
Zhaoshen LiChanghai Clinical Research Unit, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.
Feng LiuDigestive Endoscopy Center, Shanghai Tenth People's Hospital, Shanghai, China.
Yiqi DuPancreatic Intensive Care Unit, Changhai Hospital, Naval Medical University, Shanghai, China.
Xiangyu KongChanghai Clinical Research Unit, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate whether serum exosomal microRNAs (miRNAs) could be potential biomarkers in predicting acute pancreatitis (AP) with persistent organ failure (POF) at an early phase.

backgroundNovel biomarkers are sorely needed for early prediction of POF in patients with AP.

methodsIn the discovery stage, exosomal miRNAs were profiled in sera from APs with or without POF (5 vs 5) using microarrays. POF-associated miRNA signatures then were assessed in the training cohort (n = 227) and further validated in 3 independent cohorts (n = 516), including one nested case-control cohort.

resultsA total of 743 APs were recruited in this large-scale biomarker identification study with a nested case-control study. Data from the discovery cohort demonstrated that 90 exosomal miRNAs were significantly dysregulated in APs with POF compared with controls. One miRNA classifier (Cmi) comprising 3 miRNAs (miR-4265, 1208, 3127-5p) was identified in the training cohort and was further evaluated in 2 validation cohorts for their predictive value for POF. Area under the curves for Cmi ranged from 0.88 to 0.90, which was statistically superior to area under the curves of Acute Physiology and Chronic Health Examination-II and bedside index for severity in AP, and outperformed blood urea nitrogen and creatinine in POF prediction across all cohorts ( P < 0.05). Higher levels of Cmi indicated an increased need for intensive care unit admission, prolonged hospitalization, and elevated mortality rate, thus poor prognosis. In the nested case-control study, Cmi could help identify prediagnostic POF in postendoscopic retrograde cholangiopancreatography pancreatitis cases within "golden hours" after endoscopic retrograde cholangiopancreatography with high efficacy.

conclusionsSerum exosomal Cmi may be an early predictor for POF in AP, even within "golden hours" after AP onset. TRAIL REGISTRATION: ClinicalTrials.gov (NCT02602808).

Indexed as

ExosomesMicroRNAsMultiple Organ FailurePancreatitisAcute DiseaseAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisBiomarkersMicroRNAsacute pancreatitisbiomarkerexosomepersistent organ failure

Identifiers

PMID38323410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.